Rice Hall James & Associates LLC Sells 35,609 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Rice Hall James & Associates LLC trimmed its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 5.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 681,537 shares of the biopharmaceutical company’s stock after selling 35,609 shares during the quarter. Rice Hall James & Associates LLC’s holdings in ACADIA Pharmaceuticals were worth $12,506,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Values First Advisors Inc. bought a new stake in shares of ACADIA Pharmaceuticals in the third quarter valued at approximately $27,000. R Squared Ltd bought a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $47,000. Quest Partners LLC boosted its position in shares of ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,047 shares during the period. KBC Group NV boosted its position in shares of ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 2,044 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of ACADIA Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 1,066 shares during the period. 96.71% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ACAD shares. Guggenheim cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft started coverage on ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 target price for the company. StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Eight investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $24.00.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock opened at $20.04 on Tuesday. The stock has a fifty day moving average price of $18.03 and a two-hundred day moving average price of $16.67. ACADIA Pharmaceuticals Inc. has a 52-week low of $14.15 and a 52-week high of $26.56. The firm has a market capitalization of $3.33 billion, a P/E ratio of 25.69 and a beta of 0.37.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.